Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Research & Development (2021 - 2025)

Valion Bio has reported Research & Development over the past 5 years, most recently at $858000.0 for Q3 2025.

  • For Q3 2025, Research & Development rose 103.32% year-over-year to $858000.0; the TTM value through Sep 2025 reached $2.2 million, up 62.76%, while the annual FY2024 figure was $1.3 million, 20.66% down from the prior year.
  • Research & Development for Q3 2025 was $858000.0 at Valion Bio, up from $655000.0 in the prior quarter.
  • Over five years, Research & Development peaked at $858000.0 in Q3 2025 and troughed at $175000.0 in Q3 2021.
  • A 5-year average of $390842.1 and a median of $360000.0 in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: soared 158.85% in 2022 and later plummeted 47.76% in 2024.
  • Year by year, Research & Development stood at $313000.0 in 2021, then skyrocketed by 38.98% to $435000.0 in 2022, then dropped by 17.24% to $360000.0 in 2023, then decreased by 7.5% to $333000.0 in 2024, then surged by 157.66% to $858000.0 in 2025.
  • Business Quant data shows Research & Development for TIVC at $858000.0 in Q3 2025, $655000.0 in Q2 2025, and $335000.0 in Q1 2025.